AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01272973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
Study NCT03915262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Search for exocrine pancreatic insufficiency at week 0 and 12
Description: We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record.
Study NCT02694848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvianolate injection
Description: Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
Study NCT02694848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salvianolate injection
Description: Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
Study NCT02694848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
Study NCT02694848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
Study NCT01125228 — intervention group
Intervention type: DRUG
Intervention: Ziodovudine and Alpha Interferon
Study NCT03822351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Oleclumab
Description: Durvalumab + Oleclumab
Study NCT03822351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab
Study NCT03822351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Monalizumab
Description: Durvalumab + Monalizumab
Study NCT02582411 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy
Description: A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
Study NCT01469312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: modified pasta
Description: 50 grams carbohydrate as a single breakfast meal
Study NCT01469312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified pasta
Description: 50 grams carbohydrate as a single breakfast meal
Study NCT01156259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT based Involved Field Radiotherapy
Description: CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
Study NCT01156259 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-CRT based Involved Field Radiotherapy
Description: CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
Study NCT04112407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Phototherapy
Description: Phototherapy in the blue light spectrum
Study NCT04112407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl Peroxide
Description: Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
Study NCT04112407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard surgical site preparation with no P. acnes pretreatment
Study NCT04032392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous γδT cells
Description: Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
Study NCT03482765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1
Description: The product under investigation is a unique probiotic.
Study NCT03482765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2
Description: The product under investigation is a unique probiotic.
Study NCT03482765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study NCT02239588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)
Study NCT02239588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)
Study NCT02239588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)
Study NCT02582411 — intervention group
Intervention type: DEVICE
Intervention: Doppler Optical Coherence Tomography
Description: A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time.
Study NCT00926939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for the abstinence of smoking
Description: Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
Study NCT00926939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for submission of videos with CO sample
Description: This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
Study NCT03166319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI, including intracranial vessel wall imaging
Description: MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
Study NCT01888757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study NCT01888757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study NCT03211325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study NCT02801929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987518)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72_V27-010).
Study NCT00548964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 600-900mg of Li carbonate
Study NCT00548964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg of ketamine
Study NCT00548964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5mg/kg of ketamine
Study NCT00725413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant (Implanon)
Description: subdermal etonogestrel implant
Study NCT02681601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrawell Powder
Description: The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.
Study NCT02681601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Only
Description: Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
Study NCT02681601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OmegaRich fish oil supplement
Description: OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.
Study NCT04555421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen
Description: Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
Study NCT00772304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% / Azelastine 137 mcg
Description: single dose; 2 sprays per nostril
Study NCT03493178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
Study NCT03493178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
Study NCT03493178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
Study NCT04318444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
Study NCT04318444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a1DC + inactivated whole autologous HIV
Description: Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a1DC + conserved HIV peptides
Description: Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: a1DC + no antigen
Description: Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pgDC + inactivated whole autologous HIV
Description: Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pgDC + conserved HIV peptides
Description: Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
Study NCT03758625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pgDC + no antigen
Description: Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
Study NCT01216410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine infusion
Description: Prophylactic phenylephrine infusion after spinal and placebo antiemetics
Study NCT01216410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Group
Description: Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
Study NCT01397955 — intervention group
Intervention type: DRUG
Intervention: E2 transdermal (Julina, BAY86-5435)
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Study NCT05550792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optimizer smart
Description: The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
Study NCT01967901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care management program
Description: The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
Study NCT00241358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Study NCT00241358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMD3100
Study NCT00241358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplant
Study NCT03114774 — intervention group
Intervention type: DEVICE
Intervention: The bispectral index (BIS) monitoring
Study NCT03114774 — intervention group
Intervention type: BEHAVIORAL
Intervention: Ramsay Sedation Scale (RSS) Score monitoring
Study NCT02196142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Mannitol
Description: Drug: Placebo Mannitol
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
Study NCT04231123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with local anesthetic
Description: After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
Study NCT04231123 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PENG Block with 0,9% saline
Description: After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on Day 4 and Day 11 ± 2 days.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
Study NCT03317873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal B
Description: The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
Study NCT03131479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
Study NCT00968253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C (Cytarabine)
Description: 3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
Study NCT00365222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 /d
Study NCT03805425 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PiXL
Description: The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
Study NCT04032652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
Study NCT04032652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
Study NCT01703325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% triamcinolone , 0.05% clobetasol propionate ointment
Description: Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group
Study NCT01120535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.